Loading market data...
Wed, 16 Sept 2026
09:24:21 am
Wed, 16 Sept 2026
09:24:21 am
Synopsis
Infosys-backed 4baseCare raises ₹128 crore funding to expand AI-powered cancer diagnostics and precision oncology services globally. Check funding details, growth plans, OncoTwin platform, and international expansion strategy.
Precision oncology startup 4baseCare has raised ₹128 crore ($13.3 million) in funding, including a fresh ₹38 crore top-up round led by growX Ventures and Infosys, with participation from existing investors. The Bengaluru-based company plans to use the capital to expand its global genomics laboratory network, strengthen its AI-driven oncology platform, and improve access to precision cancer care across emerging markets.
Bengaluru-based precision oncology startup 4baseCare has raised a total of ₹128 crore ($13.3 million) in funding, strengthening its position in the rapidly growing genomics and cancer diagnostics space.
The latest ₹38 crore investment round was led by growX Ventures and Infosys, coming just months after the company secured ₹90 crore in the first close of its Series B funding round from investors including Ashish Kacholia, Lashit Sanghvi, and Yali Capital.
The funding highlights rising investor confidence in AI-driven healthcare solutions and precision medicine technologies that are transforming cancer diagnosis and treatment globally.
| Particulars | Details |
|---|---|
| Total Funding Raised | ₹128 Crore ($13.3 Million) |
| Latest Funding Round | ₹38 Crore |
| Lead Investors | growX Ventures, Infosys |
| Previous Series B Raise | ₹90 Crore |
| Headquarters | Bengaluru |
| Founded | 2019 |
The company intends to deploy the fresh capital across multiple growth initiatives aimed at expanding its global footprint.
The company is targeting underrepresented populations across:
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare specializes in genomics-based cancer diagnostics and AI-enabled clinical decision support solutions.
Its flagship platform, OncoTwin, combines:
The platform helps oncologists identify personalized treatment strategies and make more informed clinical decisions for cancer patients.
4baseCare has steadily expanded its presence across international markets and currently operates genomics laboratories in:
| Country | Presence |
|---|---|
| India | Active |
| UAE (Dubai) | Active |
| Nepal | Active |
| Philippines | Active |
The company now plans to enter 8–10 additional countries over the next 12 to 18 months, significantly broadening its global precision oncology network.
The startup is also scaling its in-hospital genomics laboratory model through collaborations with leading healthcare organizations.
These partnerships are helping bring advanced genomic testing and personalized cancer care closer to patients across different regions.
4baseCare is witnessing strong demand for precision oncology services.
| Metric | Current | Target |
|---|---|---|
| Monthly Genomic Tests | ~1,500 | 8,000–10,000 |
| Expansion Timeline | Ongoing | Next 12–18 Months |
The projected increase reflects growing adoption of genomics-driven cancer treatment approaches and increasing awareness of personalized medicine.
Traditional cancer treatments often follow standardized protocols, whereas precision oncology focuses on understanding the unique genetic makeup of each patient's tumor.
As genomic sequencing becomes more affordable and AI capabilities improve, precision medicine is emerging as one of the fastest-growing segments within global healthcare.
Cancer-focused healthcare startups have attracted significant investor interest in recent years as demand for advanced diagnostics and treatment solutions continues to rise.
Recent investments in the sector include:
| Startup | Funding Raised |
|---|---|
| Everhope Oncology | $10 Million |
| MOC Cancer Care & Research Centre | $18 Million |
| 4baseCare | $13.3 Million |
| Other Emerging Players | ErlySign, OnCare, OneCell Diagnostics |
The trend highlights increasing confidence in technology-driven healthcare innovations.
4baseCare is a Bengaluru-based precision oncology company focused on democratizing access to personalized cancer care. The company develops genomics-based diagnostic solutions and AI-powered clinical decision support tools that help oncologists make more accurate treatment decisions.
Through its proprietary technologies and expanding laboratory network, the company aims to make advanced cancer diagnostics accessible across emerging healthcare markets worldwide.
The ₹128 crore funding round marks an important milestone for 4baseCare as it accelerates its mission to expand precision oncology access globally. With strong backing from investors including Infosys and growX Ventures, the company is well-positioned to scale its genomics infrastructure, strengthen its AI-driven oncology platform, and enter new international markets.
As healthcare increasingly shifts toward personalized medicine, 4baseCare's focus on genomics, artificial intelligence, and clinical decision support places it at the center of one of the most transformative trends in modern cancer care.
The company has raised a total of ₹128 crore ($13.3 million).
The latest ₹38 crore round was led by growX Ventures and Infosys.
4baseCare develops genomics-based cancer diagnostics and AI-powered oncology decision support solutions.
OncoTwin is the company's AI-driven oncology platform that helps doctors derive treatment insights using clinical and genomic data.
The company currently operates in India, Dubai (UAE), Nepal, and the Philippines.
4baseCare plans to enter 8–10 new countries over the next 12–18 months and significantly increase its genomic testing volumes.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
No additional articles in this category yet.
